Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

NCT05037149 is registered in ClinicalTrials.gov with Sirnaomics as lead sponsor.

NCT NCT05037149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.
Lead sponsor
Sirnaomics
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2021
Completion date
April 25, 2024
Enrollment
50 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor